This study is testing a treatment called **PRGN-2012** for people with **Recurrent Respiratory Papillomatosis (RRP)**, a condition where growths form in the airways. The study is **open-label**, meaning everybody knows they're receiving the treatment, not a placebo. Participants must be **18 or older** and have RRP that requires surgery. They should be healthy enough for daily activities, as shown by an **ECOG performance status** of 0-1, which means they’re mostly active. People in the study will receive PRGN-2012 and be checked for safety and effectiveness for at least **12 months**. **Key Points:** * The study lasts **at least 12 months** with regular check-ups. * Participants cannot use certain medications or have severe health issues. * Pregnant women cannot join, and everyone must agree to use birth control if they can have children. Before joining, it's important to understand the study and agree to participate by signing a consent form. This study might help improve treatment options for RRP, but there are some risks and limitations.